guest ::
| Home > Publications database > Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy. > print |
| Home > Publications database > Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy. > print |
| 001 | 289225 | ||
| 005 | 20250514142829.0 | ||
| 024 | 7 | _ | |a 10.1002/advs.202401061 |2 doi |
| 024 | 7 | _ | |a pmid:38569519 |2 pmid |
| 024 | 7 | _ | |a altmetric:161531254 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-00659 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 624 |
| 100 | 1 | _ | |a Liu, Chuan |b 0 |
| 245 | _ | _ | |a Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy. |
| 260 | _ | _ | |a Weinheim |c 2024 |b Wiley-VCH |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1718960683_26627 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2024 Jun;11(23):e2401061 |
| 520 | _ | _ | |a The heterogeneity of macrophages influences the response to immune checkpoint inhibitor (ICI) therapy. However, few studies explore the impact of APOE+ macrophages on ICI therapy using single-cell RNA sequencing (scRNA-seq) and machine learning methods. The scRNA-seq and bulk RNA-seq data are Integrated to construct an M.Sig model for predicting ICI response based on the distinct molecular signatures of macrophage and machine learning algorithms. Comprehensive single-cell analysis as well as in vivo and in vitro experiments are applied to explore the potential mechanisms of the APOE+ macrophage in affecting ICI response. The M.Sig model shows clear advantages in predicting the efficacy and prognosis of ICI therapy in pan-cancer patients. The proportion of APOE+ macrophages is higher in ICI non-responders of triple-negative breast cancer compared with responders, and the interaction and longer distance between APOE+ macrophages and CD8+ exhausted T (Tex) cells affecting ICI response is confirmed by multiplex immunohistochemistry. In a 4T1 tumor-bearing mice model, the APOE inhibitor combined with ICI treatment shows the best efficacy. The M.Sig model using real-world immunotherapy data accurately predicts the ICI response of pan-cancer, which may be associated with the interaction between APOE+ macrophages and CD8+ Tex cells. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a APOE+ macrophages |2 Other |
| 650 | _ | 7 | |a immune checkpoint inhibitor |2 Other |
| 650 | _ | 7 | |a machine learning algorithm |2 Other |
| 650 | _ | 7 | |a pan‐cancer |2 Other |
| 650 | _ | 7 | |a single‐cell RNA sequencing |2 Other |
| 700 | 1 | _ | |a Xie, Jindong |b 1 |
| 700 | 1 | _ | |a Lin, Bo |b 2 |
| 700 | 1 | _ | |a Tian, Weihong |b 3 |
| 700 | 1 | _ | |a Wu, Yifan |b 4 |
| 700 | 1 | _ | |a Xin, Shan |b 5 |
| 700 | 1 | _ | |a Hong, Libing |b 6 |
| 700 | 1 | _ | |a Li, Xin |0 P:(DE-He78)128e4949aa4cb04fe109c52df0c67732 |b 7 |u dkfz |
| 700 | 1 | _ | |a Liu, Lulu |b 8 |
| 700 | 1 | _ | |a Jin, Yuzhi |b 9 |
| 700 | 1 | _ | |a Tang, Hailin |b 10 |
| 700 | 1 | _ | |a Deng, Xinpei |b 11 |
| 700 | 1 | _ | |a Zou, Yutian |0 0000-0002-5205-9923 |b 12 |
| 700 | 1 | _ | |a Zheng, Shaoquan |b 13 |
| 700 | 1 | _ | |a Fang, Weijia |b 14 |
| 700 | 1 | _ | |a Cheng, Jinlin |b 15 |
| 700 | 1 | _ | |a Dai, Xiaomeng |b 16 |
| 700 | 1 | _ | |a Bao, Xuanwen |0 0000-0002-6232-3783 |b 17 |
| 700 | 1 | _ | |a Zhao, Peng |b 18 |
| 773 | _ | _ | |a 10.1002/advs.202401061 |g p. 2401061 |0 PERI:(DE-600)2808093-2 |n 23 |p e2401061 |t Advanced science |v 11 |y 2024 |x 2198-3844 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289225/files/Advanced%20Science%20-%202024%20-%20Liu%20-%20Pan%E2%80%90Cancer%20Single%E2%80%90Cell%20and%20Spatial%E2%80%90Resolved%20Profiling%20Reveals%20the%20Immunosuppressive%20Role%20of.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/289225/files/Advanced%20Science%20-%202024%20-%20Liu%20-%20Pan%E2%80%90Cancer%20Single%E2%80%90Cell%20and%20Spatial%E2%80%90Resolved%20Profiling%20Reveals%20the%20Immunosuppressive%20Role%20of.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:289225 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)128e4949aa4cb04fe109c52df0c67732 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ADV SCI : 2022 |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2018-07-06T12:17:41Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2018-07-06T12:17:41Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2018-07-06T12:17:41Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2018-07-06T12:17:41Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-29 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-29 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-29 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |d 2023-08-29 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b ADV SCI : 2022 |d 2023-08-29 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-29 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-29 |
| 920 | 1 | _ | |0 I:(DE-He78)F180-20160331 |k F180 |l Chronische Entzündung und Krebs |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D440-20160331 |k D440 |l Chronische Entzündung und Krebs |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F180-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D440-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|